A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection
A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection
复制标题
DOI：
10.1086/386344
复制
发表时间：
2004-06-01
影响因子：
6.4
通讯作者：
Fauci, AS
中科院分区：
文献类型：
--
作者：
Dybul, M;Nies-Kraske, E;Fauci, AS
背景。我们之前证明，短周期结构化间歇治疗（SIT； 7天不治疗，然后7天抗逆转录病毒治疗[ART]）与利托那韦增强，以茚地那韦为基础，每天两次的方案维持抑制血浆HIV病毒血症，同时降低血清脂质水平。对某些患者来说，坚持这样的治疗方案可能会有问题。8例接受联合抗逆转录病毒治疗的患者血浆HIV RNA持续受到抑制
Background. We previously demonstrated that short-cycle structured intermittent therapy ( SIT; 7 days without therapy followed by 7 days with antiretroviral therapy [ART]) with a ritonavir-boosted, indinavir-based, twice-daily regimen maintained suppression of plasma HIV viremia while reducing serum levels of lipids. Adherence to such a regimen may be problematic for certain patients.Methods. Eight patients with a history of receiving combination ART that maintained suppression of plasma HIV RNA to